Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 39 of 116

  1. CCRT with Maintenance Tislelizumab and Metronomic Capecitabine

    BEONE MEDICINES AUS PTY LTD

    Nasopharyngeal Carcinoma

    phase 2 other active

    1 trial

  2. CD123 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia

    phase 2 mab active

    2 trials

  3. CD123 targeted CAR-NK cells

    Chongqing Precision Biotech Co., Ltd

    Acute Myeloid Leukemia

    phase 2 mab active

    1 trial

  4. CD19 CAR T-Cell(CAT19T2)

    Zhujiang Hospital

    B-cell Acute Lymphoblastic Leukemia

    phase 2 mab terminated

    1 trial

  5. CD19 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia

    phase 2 mab active

    2 trials

  6. CD19 CAR-T cells

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

  7. CD19 CAR-T cells and CD19 positive feeder T cells

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia in Remission

    phase 2 mab active

    1 trial

  8. CD19 and CD22 targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia, B-cell

    phase 2 mab active

    2 trials

  9. CD19 and CD22 targeted prime CAR- T cells

    Chongqing Precision Biotech Co., Ltd

    B Cell Lymphoma

    phase 2 mab active

    1 trial

  10. CD19 or CD20 CAR T cells briging HSCT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lymphoma, Large B-Cell, Diffuse

    phase 2 mab active

    1 trial

  11. CD19X CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Large B-Cell Lymphoma (LBCL)

    phase 2 small molecule active

    1 trial

  12. CD22/CD19 CAR T and auto-HSCT "sandwich" strategy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Acute Lymphoblastic Leukemia

    phase 2 other active

    1 trial

  13. CDZR123A02101

    Novartis Pharmaceuticals

    advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, or other advanced/metastatic solid tumors, ovarian clear cell cancer, endometrial carcinoma, lymphoma including peripheral T-cell Lymphoma and GCBDLBCL, malignant pleural or peritoneal mesothelioma, metastatic castration - resistant prostate cancer (mCRPC))

    phase 2 small molecule active

    1 trial

  14. CDZR123A12107

    Novartis Pharmaceuticals

    Metastatic castrate resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  15. CDZR123C12101

    Novartis Pharmaceuticals

    Metastatic hormone-sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  16. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Solid Tumor

    phase 2 mab active

    1 trial

  17. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Gastric Cancer

    phase 2 mab active

    3 trials

  18. CECI830A12101

    Novartis Pharmaceuticals

    Advanced solid tumors, Advanced HR+/HER2- breast cancer

    phase 2 small molecule active

    1 trial

  19. CEMIPLIMAB

    Fondazione Telethon ETS

    surgically resectable, high risk stage III/IV (M0) Cutaneaous Squamous Cell Carcinoma, Cutaneaous Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  20. CEP-701

    Teva Pharma GmbH

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  21. CEP-701

    Teva Pharma GmbH

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  22. CEP-701 60mg

    Teva Pharma GmbH

    Leukemia, Myeloid

    phase 2 small molecule completed

    1 trial

  23. CEP-9722

    Teva Pharma GmbH

    Solid Tumors

    phase 2 small molecule terminated

    1 trial

  24. CETUXIMAB for ADCC, Colorectal Cancer

    Fondazione Telethon ETS

    ADCC, Colorectal Cancer

    phase 2 small molecule active

    1 trial

  25. CF102

    Can-Fite BioPharma

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    2 trials

  26. CG0070

    CG Oncology

    Non Muscle Invasive Bladder Cancer

    phase 2 mab completed

    1 trial

  27. CG0070

    CG Oncology

    Bladder Cancer

    phase 2 mab completed

    1 trial

  28. CGT4859

    Cogent Biosciences

    Intrahepatic Cholangiocarcinoma (Icc)

    phase 2 small molecule active

    1 trial

  29. CGT9486

    Cogent Biosciences

    Gastrointestinal Stromal Tumors

    phase 2 small molecule completed

    1 trial

  30. CGVV858A12101

    Novartis Pharmaceuticals

    Advanced HR+/HER- breast cancer

    phase 2 small molecule active

    1 trial

  31. CHALLENGE

    Fondazione Telethon ETS

    stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  32. CHO-H01

    Cho Pharma

    Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  33. CHOP+selinexor+5-Azacitidine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Peripheral T Cell Lymphoma

    phase 2 small molecule active

    1 trial

  34. CIALIS 5 mg film-coated tablets

    The George Institute

    sexual/ erectile function in women and men after treatment for rectal cancer

    phase 2 small molecule active

    1 trial

  35. CIBI3009A101

    Talion

    Extensive-Stage Small Cell Lung Cancer

    phase 2 other active

    1 trial

  36. CIK

    The First People's Hospital of Lianyungang

    Lung Adenocarcinoma

    phase 2 mab terminated

    1 trial

  37. CIRCULATE-SPAIN-01

    The George Institute

    Localised Colon Cancer (stage II-III)

    phase 2 small molecule active

    1 trial

  38. CJDQ443A12101

    Novartis Pharmaceuticals

    Advance solid tumors harboring the KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  39. CJDQ443E12101

    Novartis Pharmaceuticals

    Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors

    phase 2 small molecule active

    1 trial

  40. CJSB462B12201

    Novartis Pharmaceuticals

    Metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  41. CJSB462C12201

    Novartis Pharmaceuticals

    Metastatic hormone-sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  42. CL1-65487-003

    The George Institute

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  43. CL1-95012-001

    The George Institute

    Soild Tumors

    phase 2 small molecule active

    1 trial

  44. CL1-95029-002

    The George Institute

    MSI-H/dMMR Gastric cancer, MSI-H/dMMR Gastroesophageal-junction Cancer

    phase 2 small molecule active

    1 trial

  45. CL1-95035-001

    The George Institute

    MTAP-deleted advanced or metastatic solid tumors

    phase 2 small molecule active

    1 trial

  46. CLARITY-PT01

    AstraZeneca AB

    Gastric Cancer, Gastroesophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  47. CLEAN-DUCT

    The George Institute

    Extrahepatic cholangiocarcinoma (eCCA)

    phase 2 small molecule active

    1 trial

  48. CLEE011Q12101

    Novartis Pharmaceuticals

    Relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.